NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. With headquarters in Fort Myers, FL, NeoGenomics is leaving its mark across the US with labs in Nashville, TN, Irvine, CA and Fort Myers. The company has a broad array of interest because it services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States.

NeoGenomics announced yesterday that Douglas M. VanOort has joined the Company’s Board of Directors and has been appointed Executive Chairman and Interim Chief Executive Officer.

VanOort has held executive leadership positions with several world-class Fortune 500 firms and rapidly-growing ventures during his 30-year career. He spent over 10 years in health-care services, first as Executive Vice President and Chief Financial Officer of Corning Life Sciences, Inc. and then as Senior Vice President, Operations at Quest Diagnostics, Inc. At Corning Life Sciences, he helped build and engineer the spinoff of two leading publically-traded NYSE life-science companies, Quest Diagnostics, Inc. and Covance, Inc, ultimately joining Quest at the time of the spin-off.

While the addition of VanOort is a major acquisition for NeoGenomics, he has shown his belief in the company not just as their leader but also as an investor. VanOort showed his devotion to the company when he made a $500,000 investment into NeoGenomics by purchasing 625,000 shares of common stock at a purchase price of $0.80 per share.

With a vast array of coverage in the marketplace and a leader like Douglas M. VanOort at the helm, NeoGenomics is poised to become a power in the future.

Let us hear your thoughts below: